Theriva Biologics, Inc.
TOVX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2,929 | $3,061 | $2,359 |
| - Cash | $7,528 | $12,120 | $10,014 | $11,609 |
| + Debt | $2,087 | $1,252 | $2,855 | $1,565 |
| Enterprise Value | – | -$7,939 | -$4,098 | -$7,685 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$27 |
| % Margin | – | – | – | – |
| EBITDA | -$4,333 | -$13,105 | -$4,370 | -$4,420 |
| % Margin | – | – | – | – |
| Net Income | -$4,361 | -$13,058 | -$4,324 | -$4,447 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.45 | -1.93 | -1.55 | -1.6 |
| % Growth | 76.7% | -24.5% | 3.1% | – |
| Operating Cash Flow | -$4,319 | -$4,712 | -$4,756 | -$4,691 |
| Capital Expenditures | -$19 | -$16 | $0 | $0 |
| Free Cash Flow | -$4,338 | -$4,728 | -$4,756 | -$4,691 |